Stereoselective delivery and actions of beta receptor antagonists

Biochemical Pharmacology

Volumn 37, Issue 1, 1988, Pages 115-124

  Walle, Thomas ^a   Webb, Jerry G ^a   Bagwell, Ervin E ^a   Walle, U Kristina ^a   Daniell, Herman B ^a   Gaffney, Thomas E ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

PRIORITY JOURNAL; REVIEW; STEREOSPECIFICITY;

ADRENERGIC BETA-ANTAGONISTS; BLOOD PROTEINS; HUMAN; NEURONS; STEREOISOMERISM; SUPPORT, U.S. GOV'T, P.H.S.; TISSUE DISTRIBUTION;

EID: 0023868442     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(88)90763-0     Document Type: Article

References (47)

1. 2-adrenoceptors
2. Studies on the antihypertensive action of the optical isomers of propranolol in man
3. Stereochemistry of the in vivo disposition and metabolism of propranolol in dog and man using deuterium-labeled pseudoracemates
4. Plasma levels of (+) and (−)-propranolol and 4-hydroxy-propranolol after administration of racemic (±)-propranolol in man
5. Stereo-selective disposition and glucuronidation of propranolol in humans
6. Food effects on propranolol systemic and oral clearance: Support for a blood flow hypothesis
7. Cosegregation of propranolol metabolism with the debri-soquine and mephenytoin polymorphisms
8. Quantitative account of propranolol metabolism in urine of normal man
9. The inhibitory effect of propranolol pretreatment on its own metabolism in the rat
10. Oxidative metabolism of propranolol is catalyzed by two different P-450 activities
11. Selective induction of propranolol metabolism by smoking; additional effects on renal clearance of metabolites
12. Stereoselective ring oxidation of propranolol in man
13. Stereoselective sulfate conjugation of 4-hydroxypropranolol in vitro by different species
14. Partial metabolic clearances as determinants of the oral bioavailability of propranolol
15. Polymorphic ability to metabolize propranolol alters 4-hydroxypropranolol levels but not beta blockade
16. The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol
17. Plasma propranolol levels in the quantitative assessment of β-adrenergic blockade in man
18. 4-Hydroxypropranolol and its glucuronide after single and long-term doses of propranolol
19. Differential Stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers
20. The molecular mechanisms of two common polymorphisms of drug oxidation—evidence for functional changes in cytochrome P-450 isozymes catalyzing bufuralol and mephenytoin oxidation
21. 3H) in man, the dog and the rat
22. Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers
23. Stereo- and regioselectivity of hepatic oxidation in man-Effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation
24. Kinetics and metabolism of (+)-, (−)- and (±)-bufuralol
25. Pharmacokinetics and dynamics of penbutolol in humans: Evidence for pathway-specific stereoselective clearance
26. Stereoselectivity in the metabolism of the β-adrenergic blocking agent, (±)-1-tert-butylamino-3-(2,3-dimethylphenoxy)-2-propanol hydrochloride (xibenolol hydrochloride, D-32), in man
27. m) and loss of stereo-selectivity of bufuralol 1'-hydroxylation in poor metabolizers
28. Genetic polymorphism in drug oxidation: In vitro studies of human debrisoquine 4-hydroxylase and bufuralol 1'-hydroxylase activities
29. Oxidation of (R) and (S)-propranolol in human and dog liver microsomes. Species differences in stereoselectivity
30. Stereoselective oxidative metabolism of propranolol in the microsomal fraction from rat and human liver. Use of deuterium labeling and pseudoracemic mixtures
31. Stereoselective clearance and distribution of intravenous propranolol
32. A physiological approach to hepatic drug clearance
33. 1 acid glycoprotein and albumin
34. Stereo-selective binding of the (−)-enantiomer of propranolol to plasma and extravascular binding sites in the dog
35. Propranolol disposition after acute myocardial infarction
36. 1 acid glycoprotein
37. 1-acid glycoprotein and propranolol binding
38. Stereoselective renal clearance of pindolol in humans
39. Stimulation induced release of propranolol and norepinephrine from adrenergic neurons
40. Adrenergic nerve stimulation-induced release of propranolol from the perfused hind-limb and spleen of the dog and associated changes in postjunctional response
41. Exercise-induced increments in plasma levels of propranolol and norepinephrine
42. Accumulation, subcellular localization and release of propranolol from synaptosomes of rat cerebral cortex
43. Depolarization-induced release of propranolol and atenolol from rat cortical synaptosomes
44. PC12 pheochromocytoma cultures in neurobiological research
45. Stereoselective storage and release of atenolol from cultured PC12 cells
46. 3H]atenolol by adrenergic storage granules isolated from PC12 cells
47. Steady-state kinetics of catecholamine transport by chromaffin-granule ‘ghosts’